News Medical on MSN
State bans on prior authorization show limited impact on buprenorphine treatment retention
State laws that ban insurance prior authorization for buprenorphine-a leading medication for opioid use disorder-may not help more patients stay in treatment for the recommended minimum of 180 days, ...
Columnist Desiree Lama finds herself having to argue that a medicine that she has been taking for migraines for years is still needed.
Why do I need a prior authorization for something that I am already prior-authorized to take? If my doctor says that they want me on a medication, why does my insurance have another say in that?” — ...
This once-weekly C-type natriuretic peptide analog functions by antagonizing overactive FGFR3 signaling to improve growth in pediatric patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results